Tirzepatide Sleep Apnea SURMOUNT-OSA Trial Results
The SURMOUNT-OSA Phase 3 trials found tirzepatide reduced apnea-hypopnea index by ~25 events/hr vs. ~5 for placebo in obese adults with OSA.
The SURMOUNT-OSA Phase 3 trials found tirzepatide reduced apnea-hypopnea index by ~25 events/hr vs. ~5 for placebo in obese adults with OSA.